Zhongheng Group announced that Zhongheng Yixin, a wholly-owned subsidiary of the company, plans to transfer 34% of its shares in Fosun Pharmaceutical Co., Ltd. through public listing. The minimum listing price is not less than 11.1373 million yuan. The final transaction amount and counterparty are subject to the public listing results. After the transfer is completed, Zhongheng Yixin will no longer hold the underlying shares. The transaction has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for review, it does not constitute a major asset restructuring, and there is uncertainty about the transaction results.

Zhongheng Group announced that Zhongheng Yixin, a wholly-owned subsidiary of the company, plans to transfer 34% of its shares in Fosun Pharmaceutical Co., Ltd. through public listing. The minimum listing price is not less than 11.1373 million yuan. The final transaction amount and counterparty are subject to the public listing results. After the transfer is completed, Zhongheng Yixin will no longer hold the underlying shares. The transaction has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for review, it does not constitute a major asset restructuring, and there is uncertainty about the transaction results.